Veterinary Medicines

Biofel PCH, injekcinė emulsija katėms

Authorised
  • Felid herpesvirus 1, Inactivated
  • Feline calicivirus, strain F9, Inactivated
  • Feline panleucopenia virus, Inactivated
Download as PDF

Product identification

Medicine name:
Biofel PCH, injekcinė emulsija katėms
Active substance:
  • Felid herpesvirus 1, Inactivated
  • Feline calicivirus, strain F9, Inactivated
  • Feline panleucopenia virus, Inactivated
Target species:
  • Cat
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Felid herpesvirus 1, Inactivated
    1.00
    relative potency
    /
    1.00
    Dose
  • Feline calicivirus, strain F9, Inactivated
    1.00
    relative potency
    /
    1.00
    Dose
  • Feline panleucopenia virus, Inactivated
    1.00
    relative potency
    /
    1.00
    Dose
Pharmaceutical form:
  • Emulsion for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI06AA04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription except for some pack sizes
Authorisation status:
  • Valid
Authorised in:
  • Lithuania
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Bioveta a.s.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Bioveta, a.s.
Responsible authority:
  • State Food And Veterinary Service
Authorisation number:
  • LT/2/17/2421/001-007
Date of authorisation status change:

Documents

RV2421.pdf

Lithuanian (PDF)
Published on: 1/09/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."